ViewPoints Interview: Albert Labs’ Dr. Malcolm Barratt-Johnson Shares Insights on Psychedelic-Assisted Therapies
Written by Tuba Khan,
In an interview with PharmaShots, Dr. Malcolm Barratt-Johnson, Chief Medical Officer of Albert Labs shared his views on the psychedelic’s therapies, the companies’ business model and your plans for scaling the psychedelics therapies.
Albert Labs will be the first psychedelics company to use an accelerated pathway, known as RWE studies, to swiftly provide access to patients in need. They’ll also own the study data to improve and protect their psychedelic-based therapies
The company submitted applications for psychedelics research and dealer’s licenses, which will allow the company to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT